Company news

C4 Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

April 8, 2024

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

April 7, 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

March 4, 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

March 3, 2024

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

February 21, 2024

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

January 8, 2024

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

January 3, 2024

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

December 11, 2023

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

December 11, 2023

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

November 27, 2023

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

November 19, 2023

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

October 31, 2023

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple My...

October 10, 2023

C4 Therapeutics Announces Chief Financial Officer Succession

September 4, 2023

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 7, 2023

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 16, 2023

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

July 4, 2023

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

June 19, 2023

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 29, 2023

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 3, 2023

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

April 18, 2023

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

February 22, 2023

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

February 7, 2023

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

January 29, 2023

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

January 8, 2023

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

November 2, 2022

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

September 28, 2022

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

September 25, 2022

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

August 3, 2022

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors

August 1, 2022

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

May 15, 2022

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 4, 2022

C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

April 7, 2022

C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

March 15, 2022

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

March 8, 2022

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

March 7, 2022

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

February 23, 2022

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

January 9, 2022

C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

C4 Therapeutics Added to NASDAQ Biotechnology Index

December 16, 2021

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

November 9, 2021

C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

August 10, 2021

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma

August 10, 2021

C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

June 20, 2021

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

June 20, 2021

C4 Therapeutics Announces Pricing of Public Offering

June 15, 2021

C4 Therapeutics Launches Proposed Public Offering

June 13, 2021

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies

June 13, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 37 decks. Every deck is listed under its year.